Anti-HLA-E Purified

Anti-HLA-E Purified
Regulatory status
RUO
Antigen
HLA-E
Clone
MEM-E/08
Format
Purified
Reactivity
Human
Application
IP, FC (QC tested)
Variant
0.1 mg
11-398-C100
In stock

0.025 mg
11-398-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1
Specificity
The antibody MEM-E/08 recognized native surface-expressed HLA-E, but not denaturated heavy chain of HLA-E. HLA-E belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on many types of the human cells. The published results revealed that antibody is remarkably specific for HLA-E, only with weak cross-reactivity with following classical MHC Class I molecules (MHC Class Ia): HLA-A24, -B7, -B27, -B51, -B54, -C7.
Application
IP, FC (QC tested)
Reactivity
Human
Immunogen
Bacterially expressed recombinant HLA-E refolded with beta2-microglobulin and peptide.
Other names
HLA class I histocompatibility antigen, alpha chain E, MHC class I antigen E
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le VT, Galun E, Horejsi V, Isakov O, Shomron N, Wolf DG, Hengel H, Mandelboim O: MicroRNA editing facilitates immune elimination of HCMV infected cells. PLoS Pathog. 2014 Feb 27;10(2):e1003963.
PubMed
Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. 2011 Sep;13(9):822-30.
PubMed
Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsí V, Goldman-Wohl D, Yagel S, Mandelboim O: The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol. 2005 Oct 15;175(8):4866-74.
PubMed
Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP.: HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol. 2005 Jan;66(1):1-12.
PubMed
Sibilio L. et al., Tissue Antigens 62, 339, 2003. (Abstract 45 from the 3rd Int. Conference on HLA-G, Paris, July 2003).
Variant
0.1 mg
11-398-C100
In stock

0.025 mg
11-398-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock